首页 > 最新文献

Journal of Endovascular Therapy最新文献

英文 中文
Updated Trends in Inferior Vena Cava Filter Use by Indication in the United States After Food and Drug Administration Safety Warnings: A Decade Analysis From 2010 to 2019. 美国食品和药物管理局发出安全警告后,按适应症分列的下腔静脉滤器最新使用趋势:从 2010 年到 2019 年的十年分析。
IF 1.7 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-01 Epub Date: 2023-03-01 DOI: 10.1177/15266028231156089
Titilope Olanipekun, Charles Ritchie, Temidayo Abe, Valery Effoe, Abimbola Chris-Olaiya, Isaac Biney, Young M Erben, Pramod Guru, Devang Sanghavi
<p><strong>Background: </strong>Overall inferior vena cava filter (IVCF) utilization has decreased in the United States since the 2010 US Food and Drug Administration (FDA) safety communication. The FDA renewed this safety warning in 2014 with additional mandates on reporting IVCF-related adverse events. We evaluated the impact of the FDA recommendations on IVCF placements for different indications from 2010 to 2019 and further assessed utilization trends by region and hospital teaching status.</p><p><strong>Methods: </strong>Inferior vena cava filter placements between 2010 and 2019 were identified in the Nationwide Inpatient Sample database using the associated International Classification of Diseases, Ninth Revision, Clinical Modification, and Tenth Revision codes. Inferior vena cava filter placements were categorized by indication for venous thromboembolism (VTE) "treatment" in patients with VTE diagnosis and contraindication to anticoagulation and "prophylaxis" in patients without VTE. Generalized linear regression was used to analyze utilization trends.</p><p><strong>Results: </strong>A total of 823 717 IVCFs were placed over the study period, of which 644 663 (78.3%) were for VTE treatment and 179 054 (21.7%) were for prophylaxis indications. The median age for both categories of patients was 68 years. The total number of IVCFs placed for all indications decreased from 129 616 in 2010 to 58 465 in 2019, with an aggregate decline rate of -8.4%. The decline rate was higher between 2014 and 2019 than between 2010 and 2014 (-11.6% vs -7.2%). From 2010 to 2019, IVCF placement for VTE treatment and prophylaxis trended downward at rates of -7.9% and -10.2%, respectively. Urban nonteaching hospitals saw the highest decline for both VTE treatment (-17.2%) and prophylactic indications (-18.0%). Hospitals located in the Northeast region had the highest decline rates for VTE treatment (-10.3%) and prophylactic indications (-12.5%).</p><p><strong>Conclusion: </strong>The higher decline rate in IVCF placements between 2014 and 2019 compared with 2010 and 2014 suggests an additional impact of the renewed 2014 FDA safety indications on national IVCF utilization. Variations in IVCF use for VTE treatment and prophylactic indications existed across hospital teaching types, locations, and regions.</p><p><strong>Clinical impact: </strong>Inferior vena cava filters (IVCF) are associated with medical complications. The 2010 and 2014 FDA safety warnings appeared to have synergistically contributed to a significant decline in IVCF utilization rates from 2010 - 2019 in the US. IVC filter placements in patients without venous thromboembolism (VTE) declined at a higher rate than VTE. However, IVCF utilization varied across hospitals and geographical locations, likely due to the absence of universally accepted clinical guidelines on IVCF indications and use. Harmonization of IVCF placement guidelines is needed to standardize clinical practice, thereby reducing the obs
背景:自2010年美国食品和药物管理局(FDA)发布安全通报以来,美国下腔静脉滤器(IVCF)的总体使用率有所下降。2014年,FDA更新了这一安全警告,并增加了报告IVCF相关不良事件的规定。我们评估了FDA的建议对2010年至2019年不同适应症下IVCF置入的影响,并进一步评估了不同地区和医院教学状况下的使用趋势:使用相关的《国际疾病分类》第九版、临床修订版和第十版代码,在全国住院病人抽样数据库中确定了 2010 年至 2019 年期间的下腔静脉滤器植入情况。根据静脉血栓栓塞(VTE)诊断和抗凝禁忌症患者的静脉血栓栓塞(VTE)"治疗 "指征和无静脉血栓栓塞患者的 "预防 "指征,对下腔静脉滤器置入情况进行分类。采用广义线性回归分析使用趋势:研究期间共放置了 823 717 个 IVCF,其中 644 663 个(78.3%)用于治疗 VTE,179 054 个(21.7%)用于预防。两类患者的年龄中位数均为 68 岁。用于所有适应症的 IVCF 总数从 2010 年的 129 616 例降至 2019 年的 58 465 例,总下降率为 -8.4%。2014年至2019年的下降率高于2010年至2014年(-11.6% vs -7.2%)。从 2010 年到 2019 年,用于治疗和预防 VTE 的 IVCF 置入率呈下降趋势,降幅分别为 -7.9% 和 -10.2%。城市非教学医院在 VTE 治疗(-17.2%)和预防适应症(-18.0%)方面的降幅最大。东北地区医院的 VTE 治疗(-10.3%)和预防性适应症(-12.5%)下降率最高:结论:与2010年和2014年相比,2014年至2019年期间IVCF置入量的下降率更高,这表明2014年FDA更新的安全适应症对全国IVCF的使用产生了额外影响。不同教学类型、地点和地区的医院在使用 IVCF 治疗 VTE 和预防适应症方面存在差异:临床影响:下腔静脉滤器(IVCF)与医疗并发症有关。2010年和2014年美国食品和药物管理局发布的安全警告似乎共同促成了2010-2019年美国IVCF使用率的显著下降。无静脉血栓栓塞症(VTE)患者的IVCF置入率降幅高于VTE。然而,不同医院和不同地区的 IVCF 使用情况各不相同,这可能是由于缺乏普遍接受的 IVCF 适应症和使用临床指南。有必要统一IVCF置入指南,以规范临床实践,从而减少观察到的地区和医院差异以及潜在的IVC过滤器过度使用。
{"title":"Updated Trends in Inferior Vena Cava Filter Use by Indication in the United States After Food and Drug Administration Safety Warnings: A Decade Analysis From 2010 to 2019.","authors":"Titilope Olanipekun, Charles Ritchie, Temidayo Abe, Valery Effoe, Abimbola Chris-Olaiya, Isaac Biney, Young M Erben, Pramod Guru, Devang Sanghavi","doi":"10.1177/15266028231156089","DOIUrl":"10.1177/15266028231156089","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Overall inferior vena cava filter (IVCF) utilization has decreased in the United States since the 2010 US Food and Drug Administration (FDA) safety communication. The FDA renewed this safety warning in 2014 with additional mandates on reporting IVCF-related adverse events. We evaluated the impact of the FDA recommendations on IVCF placements for different indications from 2010 to 2019 and further assessed utilization trends by region and hospital teaching status.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Inferior vena cava filter placements between 2010 and 2019 were identified in the Nationwide Inpatient Sample database using the associated International Classification of Diseases, Ninth Revision, Clinical Modification, and Tenth Revision codes. Inferior vena cava filter placements were categorized by indication for venous thromboembolism (VTE) \"treatment\" in patients with VTE diagnosis and contraindication to anticoagulation and \"prophylaxis\" in patients without VTE. Generalized linear regression was used to analyze utilization trends.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 823 717 IVCFs were placed over the study period, of which 644 663 (78.3%) were for VTE treatment and 179 054 (21.7%) were for prophylaxis indications. The median age for both categories of patients was 68 years. The total number of IVCFs placed for all indications decreased from 129 616 in 2010 to 58 465 in 2019, with an aggregate decline rate of -8.4%. The decline rate was higher between 2014 and 2019 than between 2010 and 2014 (-11.6% vs -7.2%). From 2010 to 2019, IVCF placement for VTE treatment and prophylaxis trended downward at rates of -7.9% and -10.2%, respectively. Urban nonteaching hospitals saw the highest decline for both VTE treatment (-17.2%) and prophylactic indications (-18.0%). Hospitals located in the Northeast region had the highest decline rates for VTE treatment (-10.3%) and prophylactic indications (-12.5%).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The higher decline rate in IVCF placements between 2014 and 2019 compared with 2010 and 2014 suggests an additional impact of the renewed 2014 FDA safety indications on national IVCF utilization. Variations in IVCF use for VTE treatment and prophylactic indications existed across hospital teaching types, locations, and regions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Clinical impact: &lt;/strong&gt;Inferior vena cava filters (IVCF) are associated with medical complications. The 2010 and 2014 FDA safety warnings appeared to have synergistically contributed to a significant decline in IVCF utilization rates from 2010 - 2019 in the US. IVC filter placements in patients without venous thromboembolism (VTE) declined at a higher rate than VTE. However, IVCF utilization varied across hospitals and geographical locations, likely due to the absence of universally accepted clinical guidelines on IVCF indications and use. Harmonization of IVCF placement guidelines is needed to standardize clinical practice, thereby reducing the obs","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9380145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endovascular Repair of Penetrating Thoracic Aortic Ulcers Using Tubular Stent Grafts Versus Stent Grafts With a Proximal Scallop. 使用管状支架移植物与带近端扇贝的支架移植物对穿透性胸主动脉溃疡进行血管内修复。
IF 1.7 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-01 Epub Date: 2023-01-20 DOI: 10.1177/15266028221149919
Alexander Kupferthaler, Sven R Hauck, Michael Schwarz, Maximilian Kern, Julia Deinsberger, Theresa-Marie Dachs, Christoph Neumayer, Maria-Elisabeth Stelzmüller, Marek Ehrlich, Christian Loewe, Martin A Funovics

Purpose: In penetrating aortic ulcers (PAUs), limited data support tubular thoracic endovascular aortic repair (TEVAR) as a viable treatment option. For treatment of more proximal PAUs, hybrid approaches and-more recently-scalloped TEVAR (scTEVAR) have been advocated. Outcomes of scTEVAR specifically for PAUs have not yet been reported. This study reports long-term outcomes for tubular and scTEVAR in PAUs and compares the safety profile in both cohorts regarding the significantly more proximal landing zone (LZ) for scTEVAR.

Materials and methods: This single-center retrospective cohort study includes all nonacute patients treated for complicated PAU with scTEVAR and tubular TEVAR. Patient and PAU characteristics as well as procedural success, complication and reintervention rates, and all-cause and aortic mortality were analyzed.

Results: Of 212 TEVAR procedures reviewed, 21 patients with tubular TEVAR and 19 patients with scTEVAR were included. Patient and PAU characteristics were similar, and LZ was significantly more proximal in the scTEVAR cohort (p=0.0001), with similar number and types of supra-aortic revascularization procedures. Clinical success was reached in all 40 patients (100%), and reintervention rate was 2/21 (9.5%) and 1/19 (5.3%), respectively. Over the mean follow-up of 63 (TEVAR) and 53 (scTEVAR) months, clinical success was stable in all patients with one (abdominal) aortic-related mortality in the scTEVAR cohort.

Conclusion: Treatment of complicated PAUs with TEVAR as well as scTEVAR provides excellent and similar clinical success, stability of clinical success, and aortic survival with acceptable complication and reintervention rates. Scalloped TEVAR safely lengthens the proximal sealing zone to address more proximal pathologies.

Clinical impact: Treatment of asymptomatic complicated penetrating aortic ulcers (PAUs) with thoracic endovascular aortic repair (TEVAR) provides excellent clinical success and acceptable complication and reintervention rates. More patients become amenable to endovascular treatment by including scalloped TEVAR (scTEVAR) as a means to safely lengthen the proximal sealing zone to address more proximal pathologies.

目的:对于穿透性主动脉溃疡(PAU),支持管状胸腔内主动脉血管修复术(TEVAR)作为可行治疗方案的数据有限。为了治疗更近端的 PAU,人们主张采用混合方法和最近的扇形 TEVAR(scTEVAR)。专门针对 PAU 的 scTEVAR 的疗效尚未见报道。本研究报告了 PAU 管式和 scTEVAR 的长期疗效,并就 scTEVAR 明显更近的着床区(LZ)对两组患者的安全性进行了比较:这项单中心回顾性队列研究包括所有使用 scTEVAR 和管式 TEVAR 治疗复杂 PAU 的非急性期患者。研究分析了患者和 PAU 的特征以及手术成功率、并发症和再介入率、全因死亡率和主动脉死亡率:结果:在212例TEVAR手术中,21例患者接受了管式TEVAR,19例患者接受了scTEVAR。患者和PAU特征相似,scTEVAR队列中LZ明显更近(p=0.0001),主动脉上血管再通术的数量和类型相似。所有40名患者均获得临床成功(100%),再介入率分别为2/21(9.5%)和1/19(5.3%)。在平均63个月(TEVAR)和53个月(scTEVAR)的随访中,所有患者的临床成功率均保持稳定,其中scTEVAR队列中有1例(腹部)主动脉相关死亡:结论:使用 TEVAR 和 scTEVAR 治疗复杂的 PAU,可获得极佳且相似的临床成功率、临床成功率的稳定性和主动脉存活率,并发症和再介入率均可接受。扇形 TEVAR 安全地延长了近端密封区,以处理更近端的病变:临床影响:用胸腔内血管主动脉修复术(TEVAR)治疗无症状的复杂性穿透性主动脉溃疡(PAUs)可取得良好的临床成功,并发症和再介入率可接受。将扇形 TEVAR(scTEVAR)作为安全延长近端密封区的一种手段,可解决更多近端病变,从而使更多患者适合接受血管内治疗。
{"title":"Endovascular Repair of Penetrating Thoracic Aortic Ulcers Using Tubular Stent Grafts Versus Stent Grafts With a Proximal Scallop.","authors":"Alexander Kupferthaler, Sven R Hauck, Michael Schwarz, Maximilian Kern, Julia Deinsberger, Theresa-Marie Dachs, Christoph Neumayer, Maria-Elisabeth Stelzmüller, Marek Ehrlich, Christian Loewe, Martin A Funovics","doi":"10.1177/15266028221149919","DOIUrl":"10.1177/15266028221149919","url":null,"abstract":"<p><strong>Purpose: </strong>In penetrating aortic ulcers (PAUs), limited data support tubular thoracic endovascular aortic repair (TEVAR) as a viable treatment option. For treatment of more proximal PAUs, hybrid approaches and-more recently-scalloped TEVAR (scTEVAR) have been advocated. Outcomes of scTEVAR specifically for PAUs have not yet been reported. This study reports long-term outcomes for tubular and scTEVAR in PAUs and compares the safety profile in both cohorts regarding the significantly more proximal landing zone (LZ) for scTEVAR.</p><p><strong>Materials and methods: </strong>This single-center retrospective cohort study includes all nonacute patients treated for complicated PAU with scTEVAR and tubular TEVAR. Patient and PAU characteristics as well as procedural success, complication and reintervention rates, and all-cause and aortic mortality were analyzed.</p><p><strong>Results: </strong>Of 212 TEVAR procedures reviewed, 21 patients with tubular TEVAR and 19 patients with scTEVAR were included. Patient and PAU characteristics were similar, and LZ was significantly more proximal in the scTEVAR cohort (p=0.0001), with similar number and types of supra-aortic revascularization procedures. Clinical success was reached in all 40 patients (100%), and reintervention rate was 2/21 (9.5%) and 1/19 (5.3%), respectively. Over the mean follow-up of 63 (TEVAR) and 53 (scTEVAR) months, clinical success was stable in all patients with one (abdominal) aortic-related mortality in the scTEVAR cohort.</p><p><strong>Conclusion: </strong>Treatment of complicated PAUs with TEVAR as well as scTEVAR provides excellent and similar clinical success, stability of clinical success, and aortic survival with acceptable complication and reintervention rates. Scalloped TEVAR safely lengthens the proximal sealing zone to address more proximal pathologies.</p><p><strong>Clinical impact: </strong>Treatment of asymptomatic complicated penetrating aortic ulcers (PAUs) with thoracic endovascular aortic repair (TEVAR) provides excellent clinical success and acceptable complication and reintervention rates. More patients become amenable to endovascular treatment by including scalloped TEVAR (scTEVAR) as a means to safely lengthen the proximal sealing zone to address more proximal pathologies.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10554983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Institutional Volume and Initial Results for Endovascular Treatment for Chronic Occlusive Lower-Extremity Artery Disease: A Report From the Japanese Nationwide Registry. 慢性闭塞性下肢动脉疾病血管内治疗的机构数量和初步结果:来自日本全国登记处的报告。
IF 1.7 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-01 Epub Date: 2023-03-19 DOI: 10.1177/15266028231161242
Takahiro Tokuda, Mitsuyoshi Takahara, Osamu Iida, Shun Kohsaka, Yoshimitsu Soga, Yasuhiro Oba, Keisuke Hirano, Toshiro Shinke, Tetsuya Amano, Yuji Ikari

Purpose: Chronic total occlusion (CTO) remains as a major target for endovascular treatment (EVT) in improving symptomatic lower-extremity artery disease (LEAD). However, despite the technical demand and learning curve for the procedure, volume-outcome relationship of EVT targeted for CTO in symptomatic LEAD remains unclear.

Materials and methods: Data were obtained from a nationwide registry for EVT procedures limited to the Japanese Association of Cardiovascular Intervention and Therapeutics between January 2018 and December 2020 from 660 cardiovascular centers in Japan. In total, 96 099 patients underwent EVT for symptomatic LEAD, and 41 900 (43.6%) underwent CTO-targeted EVTs during the study period. Institutional volume was classified into quartiles. The association of institutional volumes with short-term outcomes was explored using the generalized linear mixed model using a logit link function, in which, interinstitution variability was used as a random effect.

Results: The median institutional volume for all EVT cases per quartile was 29, 68, 125, and 299 cases/year for the first, second, third, and fourth quartiles, respectively. With each model analysis, the adjusted odds ratios (ORs) for technical success were significantly lower in patients who underwent EVT in institutions within the first quartile (<52 cases/year) than in the other quartiles (P < .01, respectively). On the contrary, the adjusted ORs for procedural complications were significantly higher in the first and second quartiles than in the third and fourth quartiles (P < .01, respectively).

Conclusion: In contemporary Japanese EVT practice, a higher institutional volume but not operator volume was associated with a higher technical success rate and a lower procedural complication rate in patients with symptomatic LEAD involving CTO lesions.

Clinical impact: EVT for CTO lesions is still challenging for clinicians because of difficulties of wire/devise crossing or high procedural complications rate. Our study demonstrated that a higher institutional volume but not operator volume was associated with a higher technical success rate and a lower procedural complication rate in patients with symptomatic LEAD involving CTO lesions. In contemporary Japanese practice, a higher institutional experience has better impacts on short-term clinical outcomes. Future research should determine the relationship between institutional volume and long-term clinical outcomes.

目的:慢性全闭塞(CTO)仍是血管内治疗(EVT)改善无症状下肢动脉疾病(LEAD)的主要目标。然而,尽管该手术的技术要求和学习曲线很高,但针对无症状下肢动脉疾病(LEAD)CTO的EVT的容量-结果关系仍不明确:2018年1月至2020年12月期间,日本心血管介入与治疗协会(Japanese Association of Cardiovascular Intervention and Therapeutics)对日本660家心血管中心的EVT手术进行了全国范围的登记。在研究期间,共有 96 099 名患者因有症状的 LEAD 而接受了 EVT,其中 41 900 人(43.6%)接受了 CTO 靶向 EVT。机构容量被分为四等分。使用Logit链接函数的广义线性混合模型探讨了机构容量与短期结果的关系,其中机构间的变异性被用作随机效应:结果:第一、第二、第三和第四四分位数的所有EVT病例中位数分别为29、68、125和299例/年。通过各模型分析,在第一四分位数内的机构接受 EVT 的患者,其调整后的技术成功几率(ORs)显著较低(P < .01)。相反,第一和第二四分位数的手术并发症调整后的几率比(ORs)明显高于第三和第四四分位数(P < .01):结论:在当代日本的EVT实践中,对于涉及CTO病变的无症状LEAD患者,较高的机构数量与较高的技术成功率和较低的手术并发症发生率相关,而与较高的操作者数量无关:临床影响:CTO病变的EVT治疗对临床医生来说仍具有挑战性,因为导线/支架交叉困难或手术并发症发生率高。我们的研究表明,在涉及 CTO 病变的无症状 LEAD 患者中,较高的机构数量(而非操作者数量)与较高的技术成功率和较低的手术并发症发生率相关。在当代日本实践中,机构经验越丰富,对短期临床结果的影响越大。未来的研究应确定机构规模与长期临床结果之间的关系。
{"title":"Institutional Volume and Initial Results for Endovascular Treatment for Chronic Occlusive Lower-Extremity Artery Disease: A Report From the Japanese Nationwide Registry.","authors":"Takahiro Tokuda, Mitsuyoshi Takahara, Osamu Iida, Shun Kohsaka, Yoshimitsu Soga, Yasuhiro Oba, Keisuke Hirano, Toshiro Shinke, Tetsuya Amano, Yuji Ikari","doi":"10.1177/15266028231161242","DOIUrl":"10.1177/15266028231161242","url":null,"abstract":"<p><strong>Purpose: </strong>Chronic total occlusion (CTO) remains as a major target for endovascular treatment (EVT) in improving symptomatic lower-extremity artery disease (LEAD). However, despite the technical demand and learning curve for the procedure, volume-outcome relationship of EVT targeted for CTO in symptomatic LEAD remains unclear.</p><p><strong>Materials and methods: </strong>Data were obtained from a nationwide registry for EVT procedures limited to the Japanese Association of Cardiovascular Intervention and Therapeutics between January 2018 and December 2020 from 660 cardiovascular centers in Japan. In total, 96 099 patients underwent EVT for symptomatic LEAD, and 41 900 (43.6%) underwent CTO-targeted EVTs during the study period. Institutional volume was classified into quartiles. The association of institutional volumes with short-term outcomes was explored using the generalized linear mixed model using a logit link function, in which, interinstitution variability was used as a random effect.</p><p><strong>Results: </strong>The median institutional volume for all EVT cases per quartile was 29, 68, 125, and 299 cases/year for the first, second, third, and fourth quartiles, respectively. With each model analysis, the adjusted odds ratios (ORs) for technical success were significantly lower in patients who underwent EVT in institutions within the first quartile (<52 cases/year) than in the other quartiles (<i>P</i> < .01, respectively). On the contrary, the adjusted ORs for procedural complications were significantly higher in the first and second quartiles than in the third and fourth quartiles (<i>P</i> < .01, respectively).</p><p><strong>Conclusion: </strong>In contemporary Japanese EVT practice, a higher institutional volume but not operator volume was associated with a higher technical success rate and a lower procedural complication rate in patients with symptomatic LEAD involving CTO lesions.</p><p><strong>Clinical impact: </strong>EVT for CTO lesions is still challenging for clinicians because of difficulties of wire/devise crossing or high procedural complications rate. Our study demonstrated that a higher institutional volume but not operator volume was associated with a higher technical success rate and a lower procedural complication rate in patients with symptomatic LEAD involving CTO lesions. In contemporary Japanese practice, a higher institutional experience has better impacts on short-term clinical outcomes. Future research should determine the relationship between institutional volume and long-term clinical outcomes.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9140260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conservative Versus Endovascular Treatment for Spontaneous Isolated Superior Mesenteric Artery Dissection: A Clinical and Imaging Follow-up Study. 自发性孤立肠系膜上动脉夹层的保守治疗与血管内治疗:临床和影像学随访研究。
IF 1.7 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-01 Epub Date: 2023-04-07 DOI: 10.1177/15266028231163733
Mengmeng Ye, Qingyun Zhou, Jiacheng Wu, Zheng Zhang, Bo Li, Tao Zheng, Guofeng Shao

Purpose: Spontaneous isolated superior mesenteric artery dissection (SISMAD) is a rare vascular disease, the treatment strategies for which remain debated. This retrospective study aimed to compare the outcomes of conservative and endovascular treatments in patients with SISMAD.

Materials and methods: Fifty-eight patients with SISMAD confirmed by computed tomography angiography admitted to our hospital between November 2017 and May 2021 and received confirmed conservative (n=43) or endovascular (n=15) treatment. The patient demographics, imaging analysis, and follow-up results were analyzed and compared.

Results: The cohort included 54 males and 4 females with a mean age of 52 years. Abdominal pain was the major complaint (49/58, 84.5%), followed by chest pain (2/58, 3.4%). The mean follow-up was 9.1±7.9 months. The 2 main Sakamoto types were type III (27/58, 46.6%) and type IV (16/58, 27.6%). Most patients in both groups had angle 1 (aortomesenteric angle) and angle 2 (superior mesenteric artery [SMA] course) of over 80°. About 67.3% of patients had long length of dissection (>60 mm). The median distance between the SMA root and the dissection entry site was 1.5 cm, mostly (84.5% of the patients) in the curved segment of the SMA. Telephone follow-ups found that most patients survived pain-free, and none underwent intestinal resection. Only 4 patients, 2 in each group, had recurrent abdominal pain during follow-up and received stenting treatment to achieve complete vascular remodeling. Importantly, we found that the conservative and endovascular therapies achieved similar high remodeling rates (94% and 100%, respectively; p=0.335). The conservative group achieved satisfying vascular remodeling (partial, 35%; complete, 59%), making it as safe and effective a treatment as endovascular therapy.

Conclusions: Initial conservative management is safe and effective in patients with SISMAD. A high technical success rate and favorable short-term outcomes were associated with endovascular procedures as secondary interventions. It would be helpful to conduct large-scale, prospective, randomized controlled trials with long-term follow-up for SISMAD.

Clinical impact: 1. This research provided more detail clinical information, such as evaluation of abdominal pain and measurements of SMA angles, which is all relevant to treatment. 2. What's more, the most surprising results of follow-up part shown that conservative treatment could reached the remodeling rate as high as endovascular treatment, which was relatively low in other studies. It helps us share our treatment experience with clinicians. 3. In addition, we get limited knowledge about this rare disease, it's encouraging us to do more researches based on the results we had.

目的:自发性孤立肠系膜上动脉夹层(SISMAD)是一种罕见的血管疾病,其治疗策略仍存在争议。这项回顾性研究旨在比较保守治疗和血管内治疗对 SISMAD 患者的疗效:2017年11月至2021年5月期间,我院收治的58例经计算机断层扫描血管造影证实的SISMAD患者,接受了确诊的保守治疗(43例)或血管内治疗(15例)。对患者的人口统计学、影像学分析和随访结果进行了分析和比较:研究对象包括 54 名男性和 4 名女性,平均年龄 52 岁。腹痛是主要主诉(49/58,84.5%),其次是胸痛(2/58,3.4%)。平均随访时间为 9.1±7.9 个月。两种主要的坂本类型是 III 型(27/58,46.6%)和 IV 型(16/58,27.6%)。两组中的大多数患者的第 1 角(主动脉肠管角)和第 2 角(肠系膜上动脉[SMA]走向)均超过 80°。约 67.3% 的患者有较长的夹层长度(>60 毫米)。SMA 根部与夹层入口之间的中位距离为 1.5 厘米,大部分(84.5% 的患者)位于 SMA 的弯曲段。电话随访发现,大多数患者在无痛情况下存活,没有人接受肠道切除术。只有 4 例患者(每组 2 例)在随访期间再次出现腹痛,并接受了支架治疗,以实现完全的血管重塑。重要的是,我们发现保守疗法和血管内治疗法获得了相似的高重塑率(分别为 94% 和 100%; p=0.335)。保守治疗组实现了令人满意的血管重塑(部分重塑,35%;完全重塑,59%),使其成为与血管内治疗同样安全有效的治疗方法:结论:对 SISMAD 患者进行初步保守治疗是安全有效的。结论:对SISMAD患者进行初步保守治疗是安全有效的,作为二次介入治疗的血管内手术具有较高的技术成功率和良好的短期疗效。临床影响:1.该研究提供了更详细的临床信息,如腹痛评估、SMA角度测量等,这些都与治疗相关。2.2.更令人惊喜的是,随访部分的结果显示,保守治疗的重塑率与血管内治疗一样高,而其他研究的重塑率相对较低。这有助于我们与临床医生分享治疗经验。3.3. 此外,我们对这种罕见疾病的了解有限,这鼓励我们根据我们的研究结果开展更多研究。
{"title":"Conservative Versus Endovascular Treatment for Spontaneous Isolated Superior Mesenteric Artery Dissection: A Clinical and Imaging Follow-up Study.","authors":"Mengmeng Ye, Qingyun Zhou, Jiacheng Wu, Zheng Zhang, Bo Li, Tao Zheng, Guofeng Shao","doi":"10.1177/15266028231163733","DOIUrl":"10.1177/15266028231163733","url":null,"abstract":"<p><strong>Purpose: </strong>Spontaneous isolated superior mesenteric artery dissection (SISMAD) is a rare vascular disease, the treatment strategies for which remain debated. This retrospective study aimed to compare the outcomes of conservative and endovascular treatments in patients with SISMAD.</p><p><strong>Materials and methods: </strong>Fifty-eight patients with SISMAD confirmed by computed tomography angiography admitted to our hospital between November 2017 and May 2021 and received confirmed conservative (n=43) or endovascular (n=15) treatment. The patient demographics, imaging analysis, and follow-up results were analyzed and compared.</p><p><strong>Results: </strong>The cohort included 54 males and 4 females with a mean age of 52 years. Abdominal pain was the major complaint (49/58, 84.5%), followed by chest pain (2/58, 3.4%). The mean follow-up was 9.1±7.9 months. The 2 main Sakamoto types were type III (27/58, 46.6%) and type IV (16/58, 27.6%). Most patients in both groups had angle 1 (aortomesenteric angle) and angle 2 (superior mesenteric artery [SMA] course) of over 80°. About 67.3% of patients had long length of dissection (>60 mm). The median distance between the SMA root and the dissection entry site was 1.5 cm, mostly (84.5% of the patients) in the curved segment of the SMA. Telephone follow-ups found that most patients survived pain-free, and none underwent intestinal resection. Only 4 patients, 2 in each group, had recurrent abdominal pain during follow-up and received stenting treatment to achieve complete vascular remodeling. Importantly, we found that the conservative and endovascular therapies achieved similar high remodeling rates (94% and 100%, respectively; p=0.335). The conservative group achieved satisfying vascular remodeling (partial, 35%; complete, 59%), making it as safe and effective a treatment as endovascular therapy.</p><p><strong>Conclusions: </strong>Initial conservative management is safe and effective in patients with SISMAD. A high technical success rate and favorable short-term outcomes were associated with endovascular procedures as secondary interventions. It would be helpful to conduct large-scale, prospective, randomized controlled trials with long-term follow-up for SISMAD.</p><p><strong>Clinical impact: </strong>1. This research provided more detail clinical information, such as evaluation of abdominal pain and measurements of SMA angles, which is all relevant to treatment. 2. What's more, the most surprising results of follow-up part shown that conservative treatment could reached the remodeling rate as high as endovascular treatment, which was relatively low in other studies. It helps us share our treatment experience with clinicians. 3. In addition, we get limited knowledge about this rare disease, it's encouraging us to do more researches based on the results we had.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9258193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Snare-Dragging Technique to Target the Hypogastric Artery in an Iliac Bifurcation Dissection. 在髂骨分叉解剖中瞄准胃下动脉的卡拖技术
IF 1.7 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-01 Epub Date: 2022-11-11 DOI: 10.1177/15266028221134885
Elena Marchiori, Julia Kirchenbauer, Abdulhakim Ibrahim, Johannes Frederik Schaefers, Alexander Oberhuber

Purpose: To describe snare-assisted vessel targeting to selectively overcome a dissection in the iliac bifurcation and gain antegrade access to the hypogastric artery (HA).

Technique: The technique is demonstrated in a 64-year-old woman with an asymptomatic Crawford type III thoracoabdominal aneurysm. A 2-stage endovascular repair, consisting of a thoracic endovascular aortic repair (TEVAR) and a branched endovascular aortic repair was planned. In the control angiography after TEVAR, a disrupted plaque with consequent dissection in the right iliac bifurcation was detected. The perfusion of the common iliac artery and external iliac artery resulted impaired. The targeting of the right HA through a contralateral antegrade approach failed, whereas an ipsilateral retrograde approach was possible but unsuitable for therapeutic purposes. Using the catheter of the retrograde ipsilateral access, a snare from a contralateral crossover was cached and dragged into the HA, allowing the targeting of the vessels and further endovascular therapy with angioplasty and stenting. Follow-up 8 months postoperatively demonstrated the patency of the stents and well-preserved perfusion in the right iliac bifurcation.

Conclusion: The snare-dragging technique can be used to gain access to vessels presenting challenging conformations or dissections. This application may be a valuable support for complex endovascular treatment in a variety of patients.

Clinical impact: The snare-dragging technique can be used to gain access to vessels presenting challenging conformations or dissections. It allows the catheterization to be establish from the easiest and safest approach and then "transferred" from one access to the other. It avoids the risk of repeated loss of catheterization due to unstable and unfavorable working angles, and it saves time and radiation. It permits different material combinations, adapting to the available resources and materials. We believe that the current technique may increase the strategy spectrum available for endovascular therapy and complex endovascular procedures.

目的:描述通过套管辅助血管靶向术选择性地克服髂骨分叉处的夹层并获得下胃动脉(HA)的前向通路:该技术在一名患有无症状克劳福德 III 型胸腹动脉瘤的 64 岁女性身上进行了演示。计划进行两阶段的血管内修复,包括胸腔血管内主动脉修复术(TEVAR)和分支血管内主动脉修复术。在 TEVAR 术后的对照血管造影中,发现右侧髂骨分叉处的斑块破裂,并随之出现夹层。髂总动脉和髂外动脉的灌注受到影响。通过对侧前向途径瞄准右侧 HA 的手术失败了,而同侧逆行途径是可行的,但不适合治疗目的。利用同侧逆行入路的导管,从对侧交叉处插入一个套管并拖入 HA,从而锁定了血管,并通过血管成形术和支架植入术进行了进一步的血管内治疗。术后8个月的随访显示,支架通畅,右髂分叉处的血流灌注保存完好:结论:套管牵引技术可用于进入具有挑战性构型或解剖的血管。临床影响:临床影响:套管拖拽技术可用于进入形态或断裂具有挑战性的血管。它允许从最简单、最安全的途径建立导管,然后从一个途径 "转移 "到另一个途径。它避免了因工作角度不稳定和不利而导致导管插入失败的风险,并节省了时间和辐射。它允许不同的材料组合,以适应现有的资源和材料。我们相信,目前的技术可以增加血管内治疗和复杂血管内手术的策略范围。
{"title":"Snare-Dragging Technique to Target the Hypogastric Artery in an Iliac Bifurcation Dissection.","authors":"Elena Marchiori, Julia Kirchenbauer, Abdulhakim Ibrahim, Johannes Frederik Schaefers, Alexander Oberhuber","doi":"10.1177/15266028221134885","DOIUrl":"10.1177/15266028221134885","url":null,"abstract":"<p><strong>Purpose: </strong>To describe snare-assisted vessel targeting to selectively overcome a dissection in the iliac bifurcation and gain antegrade access to the hypogastric artery (HA).</p><p><strong>Technique: </strong>The technique is demonstrated in a 64-year-old woman with an asymptomatic Crawford type III thoracoabdominal aneurysm. A 2-stage endovascular repair, consisting of a thoracic endovascular aortic repair (TEVAR) and a branched endovascular aortic repair was planned. In the control angiography after TEVAR, a disrupted plaque with consequent dissection in the right iliac bifurcation was detected. The perfusion of the common iliac artery and external iliac artery resulted impaired. The targeting of the right HA through a contralateral antegrade approach failed, whereas an ipsilateral retrograde approach was possible but unsuitable for therapeutic purposes. Using the catheter of the retrograde ipsilateral access, a snare from a contralateral crossover was cached and dragged into the HA, allowing the targeting of the vessels and further endovascular therapy with angioplasty and stenting. Follow-up 8 months postoperatively demonstrated the patency of the stents and well-preserved perfusion in the right iliac bifurcation.</p><p><strong>Conclusion: </strong>The snare-dragging technique can be used to gain access to vessels presenting challenging conformations or dissections. This application may be a valuable support for complex endovascular treatment in a variety of patients.</p><p><strong>Clinical impact: </strong>The snare-dragging technique can be used to gain access to vessels presenting challenging conformations or dissections. It allows the catheterization to be establish from the easiest and safest approach and then \"transferred\" from one access to the other. It avoids the risk of repeated loss of catheterization due to unstable and unfavorable working angles, and it saves time and radiation. It permits different material combinations, adapting to the available resources and materials. We believe that the current technique may increase the strategy spectrum available for endovascular therapy and complex endovascular procedures.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11403914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40464613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Favorable Remodeling After TEVAR in Uncomplicated Acute and Subacute Type B Aortic Dissection in Comparison to Conservative Treatment: A Midterm Analysis. 与保守治疗相比,无并发症的急性和亚急性 B 型主动脉夹层经 TEVAR 后重塑效果更佳:中期分析。
IF 1.7 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-01 Epub Date: 2023-03-08 DOI: 10.1177/15266028231158971
Wael Ahmad, Jan Brunkwall, Alexander C Bunck, Bernhard Dorweiler, Spyridon Mylonas
<p><strong>Purpose: </strong>The purpose of the study was to evaluate the midterm and long-term outcomes of patients who underwent thoracic endovascular aortic repair (TEVAR) procedure to treat an uncomplicated acute and subacute type B aortic dissection (uATBAD) with high risk for subsequent aortic complications compared with the group of patients who received a conservative treatment protocol during the same period.</p><p><strong>Materials and methods: </strong>Between 2008 and 2019, 35 patients who had TEVAR due to uATBAD and those with conservative procedure (n=18) were included in a retrospective analysis and follow-up study. The primary endpoints were false lumen thrombosis/perfusion, true lumen diameter, and aortic dilatation. The aortic-related mortality, reintervention, and long-term survival were the secondary endpoints.</p><p><strong>Results: </strong>In the study period, 53 patients (22 females) with a mean age of 61.1±13 years were included. No 30-day and in-hospital mortality was recorded. Permanent neurological deficits occurred in 2 patients (5.7%). In the TEVAR group (n=35) and in a median follow-up period of 34 months, a significant reduction of maximum aortic and false lumen diameter as well as a significant increase of true lumen diameter were detected (p<0.001 each). Complete false lumen thrombosis increased from 6% preoperatively to 60% at follow-up. The median difference in aortic, false lumen, and true lumen diameter was -5 mm (interquartile range [IQR]=-28 to 8 mm), -11 mm (IQR=-53 to 10 mm), and 7 mm (IQR=-13 to 17 mm), respectively. In 3 patients (8.6%), a reintervention was needed. Two patients (1 aortic-related) died during follow-up. The estimated survival according to Kaplan-Meyer analysis was 94.1% after 3 years and 87.5% after 5 years. Similar to the TEVAR group, no 30-day or in-hospital mortality was recorded in the conservative group. During follow-up, 2 patients died and 5 patients underwent conversion-TEVAR (28%). In a median follow-up period of 26 months (range=150), a significant increase of maximum aortic diameter (p=0.006) and a tendency to augmentation of the false lumen (p=0.06) were noted. No significant reduction of the true lumen was seen.</p><p><strong>Conclusions: </strong>Thoracic endovascular aortic repair in patients at high risk of subsequent aortic complications in uncomplicated acute and subacute type B aortic dissection is safe and is associated with favorable midterm outcomes regarding aortic remodeling.</p><p><strong>Clinical impact: </strong>In a retrospective, single center analysis of prospectively collected data with follow-up, we compared 35 patients with high-risk features who recieved TEVAR in acute and sub-acute uncomplicated type B aortic dissection to a control-group (n=18). The TEVAR group showed a significant positive remoduling (reduction of max. aortic and false lumen diameter and increase of true lumen diameter (p<0.001 each)) during follow-up with an estimated survival of 94
目的:该研究旨在评估接受胸腔内血管主动脉修复术(TEVAR)治疗无并发症的急性和亚急性B型主动脉夹层(uATBAD)且后续主动脉并发症风险高的患者与同期接受保守治疗方案的患者组的中期和长期疗效比较:2008年至2019年期间,35例因uATBAD而接受TEVAR的患者和接受保守治疗的患者(18例)被纳入回顾性分析和随访研究。主要终点是假腔血栓/灌注、真腔直径和主动脉扩张。主动脉相关死亡率、再次介入治疗和长期存活率为次要终点:研究期间共纳入 53 名患者(22 名女性),平均年龄为 61.1±13 岁。无30天和住院期间死亡记录。2例患者(5.7%)出现永久性神经功能缺损。在TEVAR组(35人)中,中位随访时间为34个月,发现主动脉最大直径和假腔直径显著缩小,真腔直径显著增加(p结论:对无并发症的急性和亚急性 B 型主动脉夹层患者进行胸腔内血管主动脉修补术是安全的,而且与主动脉重塑的良好中期结果相关:在一项对前瞻性收集的随访数据进行的单中心回顾性分析中,我们将急性和亚急性无并发症B型主动脉夹层中接受TEVAR的35例高风险患者与对照组(18例)进行了比较。TEVAR 组的重塑效果显著(主动脉和假腔最大直径减小,真腔直径增大(P<0.05))。
{"title":"Favorable Remodeling After TEVAR in Uncomplicated Acute and Subacute Type B Aortic Dissection in Comparison to Conservative Treatment: A Midterm Analysis.","authors":"Wael Ahmad, Jan Brunkwall, Alexander C Bunck, Bernhard Dorweiler, Spyridon Mylonas","doi":"10.1177/15266028231158971","DOIUrl":"10.1177/15266028231158971","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;The purpose of the study was to evaluate the midterm and long-term outcomes of patients who underwent thoracic endovascular aortic repair (TEVAR) procedure to treat an uncomplicated acute and subacute type B aortic dissection (uATBAD) with high risk for subsequent aortic complications compared with the group of patients who received a conservative treatment protocol during the same period.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;Between 2008 and 2019, 35 patients who had TEVAR due to uATBAD and those with conservative procedure (n=18) were included in a retrospective analysis and follow-up study. The primary endpoints were false lumen thrombosis/perfusion, true lumen diameter, and aortic dilatation. The aortic-related mortality, reintervention, and long-term survival were the secondary endpoints.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In the study period, 53 patients (22 females) with a mean age of 61.1±13 years were included. No 30-day and in-hospital mortality was recorded. Permanent neurological deficits occurred in 2 patients (5.7%). In the TEVAR group (n=35) and in a median follow-up period of 34 months, a significant reduction of maximum aortic and false lumen diameter as well as a significant increase of true lumen diameter were detected (p&lt;0.001 each). Complete false lumen thrombosis increased from 6% preoperatively to 60% at follow-up. The median difference in aortic, false lumen, and true lumen diameter was -5 mm (interquartile range [IQR]=-28 to 8 mm), -11 mm (IQR=-53 to 10 mm), and 7 mm (IQR=-13 to 17 mm), respectively. In 3 patients (8.6%), a reintervention was needed. Two patients (1 aortic-related) died during follow-up. The estimated survival according to Kaplan-Meyer analysis was 94.1% after 3 years and 87.5% after 5 years. Similar to the TEVAR group, no 30-day or in-hospital mortality was recorded in the conservative group. During follow-up, 2 patients died and 5 patients underwent conversion-TEVAR (28%). In a median follow-up period of 26 months (range=150), a significant increase of maximum aortic diameter (p=0.006) and a tendency to augmentation of the false lumen (p=0.06) were noted. No significant reduction of the true lumen was seen.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Thoracic endovascular aortic repair in patients at high risk of subsequent aortic complications in uncomplicated acute and subacute type B aortic dissection is safe and is associated with favorable midterm outcomes regarding aortic remodeling.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Clinical impact: &lt;/strong&gt;In a retrospective, single center analysis of prospectively collected data with follow-up, we compared 35 patients with high-risk features who recieved TEVAR in acute and sub-acute uncomplicated type B aortic dissection to a control-group (n=18). The TEVAR group showed a significant positive remoduling (reduction of max. aortic and false lumen diameter and increase of true lumen diameter (p&lt;0.001 each)) during follow-up with an estimated survival of 94","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9132730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive Learning Curve Analysis of a Long-Term Experience With Thoracic Endovascular Aneurysm Repair. 胸腔血管内动脉瘤修补术长期经验的综合学习曲线分析。
IF 1.7 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-01 Epub Date: 2023-03-24 DOI: 10.1177/15266028231161489
Stefano Gennai, Nicola Leone, Luigi Am Bartolotti, Francesco Andreoli, Mattia Migliari, Roberto Silingardi
<p><strong>Purpose: </strong>To analyze the learning curve for thoracic endovascular aortic repair (TEVAR) in a single center over a period of 25 years.</p><p><strong>Materials and methods: </strong>In total, 390 consecutive standard TEVAR procedures undertaken between 1996 and 2021 were included in a retrospective, observational, single-center study. Cumulative sum charts were elaborated for the entire center experience (primary outcome) as well as for the first and second implanting physicians. Data on procedural variables (contrast volume, operative and fluoroscopy time), 30-day major adverse events (MAEs) and clinical success, and endoleak and reintervention rates were secondary outcomes and subdivided into 4 quartiles of experience (Q1-Q4) or presented as first 2 versus latest 2 quartiles (Q1-Q2 vs Q3-Q4).</p><p><strong>Results: </strong>The mean follow-up was 4.3±4.0 years. The center's learning curve was achieved after 75 procedures, and it was similar for the first implanting physician. The surgeon coming thereafter had a significantly shorter curve (10 TEVARs). Comparing Q1-Q2 with Q3-Q4, 30-day MAEs (16.1 vs 11.3%, p=0.164), 30-day mortality (11.4% vs 3.6%, p=0.003), and intraoperative additional maneuvers (21.5% vs 13.3%, p=0.033) were reduced along with an improvement in clinical success (85.9% vs 90.3%, p=0.190). From Q1 to Q4, operative time (139.8±65.5 to 76.7±43.7 min, p=0.001), fluoroscopy time (15.1±8.8 to 7.1±5.1 min, p<0.001), and contrast volume (244.0±112.1 to 104.3±46.1 mL, p<0.001) showed a considerable reduction. Late endoleak and aortic-related mortality declined significantly from Q1-Q2 to Q3-Q4 (24.1% to 15.5%, p=0.033 and 18.6% vs 8.2%, p=0.006, respectively). Operative time (p=0.021), contrast volume (p=0.016), and fluoroscopy time (p=0.004) were independent risk factors for endoleak, causing a 1.3-fold risk increase for both each 60 minutes of additional operative time (p=0.021) and every 100 mL of additional contrast medium (p=0.016). Each 10-minute increase in fluoroscopy time determined a 1.4-fold risk increment (p=0.004).</p><p><strong>Conclusion: </strong>The learning curve shortened significantly over time with non-negligible clinical outcome improvements, suggesting that specific endovascular training is mandatory to become an effective TEVAR performer.</p><p><strong>Clinical impact: </strong>For the first time in literature, the standard TEVAR's learning curve has been evaluated at a single vascular surgery center over a period of 25 years. The learning curve for the center and the first physician historically undertaking TEVAR was achieved at the 75th treated patient. The learning curve of the surgeons coming thereafter was significantly shorter (10 cases). This quarter-century demonstrated that intraoperative learning-related variables were associated with long-term clinical outcomes and all have improved over time. Centers approaching TEVAR for the first time and training program providers could use these
目的:分析单个中心 25 年来胸腔内血管主动脉修复术(TEVAR)的学习曲线:一项回顾性、观察性、单中心研究共纳入了 1996 年至 2021 年间进行的 390 例连续标准 TEVAR 手术。对整个中心的经验(主要结果)以及第一位和第二位植入医生的经验进行了累积总图表分析。手术变量(造影剂用量、手术和透视时间)、30 天主要不良事件(MAE)和临床成功率、内漏率和再介入率等数据为次要结果,并细分为 4 个经验四分位数(Q1-Q4)或前 2 个四分位数与后 2 个四分位数(Q1-Q2 vs Q3-Q4):平均随访时间为 4.3±4.0 年。该中心的学习曲线是在 75 例手术后形成的,与第一位植入医生的学习曲线相似。之后的外科医生学习曲线明显较短(10 例 TEVAR)。将 Q1-Q2 与 Q3-Q4 相比,30 天 MAEs(16.1% vs 11.3%,p=0.164)、30 天死亡率(11.4% vs 3.6%,p=0.003)和术中额外操作(21.5% vs 13.3%,p=0.033)均有所减少,临床成功率也有所提高(85.9% vs 90.3%,p=0.190)。从第一季度到第四季度,手术时间(139.8±65.5 分钟到 76.7±43.7 分钟,P=0.001)、透视时间(15.1±8.8 分钟到 7.1±5.1 分钟,P=0.001)、学习曲线(139.8±65.5 分钟到 76.7±43.7 分钟,P=0.001)和临床成功率(85.9% vs 90.3%,P=0.190)均有所提高:随着时间的推移,学习曲线明显缩短,临床结果改善不可忽略,这表明要成为一名有效的 TEVAR 执行者,必须接受专门的血管内培训:临床影响:文献首次对一个血管外科中心25年来的标准TEVAR学习曲线进行了评估。该中心和历史上第一位开展 TEVAR 的医生的学习曲线是在治疗第 75 位患者时达到的。此后,外科医生的学习曲线明显缩短(10 例)。这四分之一个世纪表明,术中学习相关变量与长期临床结果有关,而且随着时间的推移,所有变量都有所改善。首次开展 TEVAR 的中心和培训计划提供者可以利用这些数据,争取提供更好的临床效果。
{"title":"Comprehensive Learning Curve Analysis of a Long-Term Experience With Thoracic Endovascular Aneurysm Repair.","authors":"Stefano Gennai, Nicola Leone, Luigi Am Bartolotti, Francesco Andreoli, Mattia Migliari, Roberto Silingardi","doi":"10.1177/15266028231161489","DOIUrl":"10.1177/15266028231161489","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;To analyze the learning curve for thoracic endovascular aortic repair (TEVAR) in a single center over a period of 25 years.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;In total, 390 consecutive standard TEVAR procedures undertaken between 1996 and 2021 were included in a retrospective, observational, single-center study. Cumulative sum charts were elaborated for the entire center experience (primary outcome) as well as for the first and second implanting physicians. Data on procedural variables (contrast volume, operative and fluoroscopy time), 30-day major adverse events (MAEs) and clinical success, and endoleak and reintervention rates were secondary outcomes and subdivided into 4 quartiles of experience (Q1-Q4) or presented as first 2 versus latest 2 quartiles (Q1-Q2 vs Q3-Q4).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The mean follow-up was 4.3±4.0 years. The center's learning curve was achieved after 75 procedures, and it was similar for the first implanting physician. The surgeon coming thereafter had a significantly shorter curve (10 TEVARs). Comparing Q1-Q2 with Q3-Q4, 30-day MAEs (16.1 vs 11.3%, p=0.164), 30-day mortality (11.4% vs 3.6%, p=0.003), and intraoperative additional maneuvers (21.5% vs 13.3%, p=0.033) were reduced along with an improvement in clinical success (85.9% vs 90.3%, p=0.190). From Q1 to Q4, operative time (139.8±65.5 to 76.7±43.7 min, p=0.001), fluoroscopy time (15.1±8.8 to 7.1±5.1 min, p&lt;0.001), and contrast volume (244.0±112.1 to 104.3±46.1 mL, p&lt;0.001) showed a considerable reduction. Late endoleak and aortic-related mortality declined significantly from Q1-Q2 to Q3-Q4 (24.1% to 15.5%, p=0.033 and 18.6% vs 8.2%, p=0.006, respectively). Operative time (p=0.021), contrast volume (p=0.016), and fluoroscopy time (p=0.004) were independent risk factors for endoleak, causing a 1.3-fold risk increase for both each 60 minutes of additional operative time (p=0.021) and every 100 mL of additional contrast medium (p=0.016). Each 10-minute increase in fluoroscopy time determined a 1.4-fold risk increment (p=0.004).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The learning curve shortened significantly over time with non-negligible clinical outcome improvements, suggesting that specific endovascular training is mandatory to become an effective TEVAR performer.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Clinical impact: &lt;/strong&gt;For the first time in literature, the standard TEVAR's learning curve has been evaluated at a single vascular surgery center over a period of 25 years. The learning curve for the center and the first physician historically undertaking TEVAR was achieved at the 75th treated patient. The learning curve of the surgeons coming thereafter was significantly shorter (10 cases). This quarter-century demonstrated that intraoperative learning-related variables were associated with long-term clinical outcomes and all have improved over time. Centers approaching TEVAR for the first time and training program providers could use these","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9161346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monocentric Evaluation of Physician-Modified Fenestrations or Parallel Endografts for Complex Aortic Diseases. 针对复杂主动脉疾病的医生改良瓣膜或平行内植物的单中心评估。
IF 1.7 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-01 Epub Date: 2023-01-16 DOI: 10.1177/15266028221149918
Siting Li, Wei Wang, Xiaoning Sun, Zhili Liu, Rong Zeng, Jiang Shao, Bao Liu, Yuexin Chen, Wei Ye, Yuehong Zheng
<p><strong>Purpose: </strong>This study aimed to investigate the demographic and anatomic characteristics, as well as perioperative and follow-up results of fenestration and parallel techniques for the endovascular repair of complex aortic diseases.</p><p><strong>Materials and methods: </strong>A retrospective study was conducted on 67 consecutive patients underwent endovascular treatment for complex aortic diseases including abdominal aortic aneurysm (AAA), thoracoabdominal aneurysm (TAAA), aortic dissection, or prior endovascular repair with either fenestrated and parallel endovascular aortic repair (f-EVAR or ch-EVAR) at a single institute from 2013 to 2021. Choices of intervention were made by the disease' emergency, patients' general condition, the anatomic characteristics, as well as following the recommendation from the devices' guidelines. Patients' clinical demographics, aortic disease characteristics, perioperative details, and disease courses were discussed. Short- and mid-term follow-up results were obtained and analyzed. Endpoints were aneurysm-related and unrelated mortality, branch instability, and renal function deterioration.</p><p><strong>Results: </strong>Totally, 34 and 27 patients received f-EVAR and ch-EVAR, while 6 patients received a combination of both. Fenestrated endovascular aortic repair was conducted mainly in AAA affecting visceral branches and TAAA, whereas ch-EVAR was normally utilized for infrarenal AAA. Regarding the average number of reconstructed arteries per patient, there was a significant difference among f-EVAR, ch-EVAR, and the combination group (mean = 2.3 ± 0.9, 1.4 ± 0.6, 3.5 ± 0.5, p<0.001). Primary technical success was achieved in 28 (82.4%), 22 (81.5%), and 3 (50.0%) patients for each group. Besides operational time (5.77 ± 2.58, 4.47 ± 1.44, p=0.033), no significant difference was observed for blood transfusion, intensive care unit (ICU) or hospital stay, blood creatinine level, 30-day complications, or follow-up complications between patients undergoing f-EVAR or ch-EVAR. Patients receiving combination of both techniques had a higher rate of blood transfusion (p=0.044), longer operational time (p=0.008) or hospital stay (p=0.017), as well as more stent occlusion (p=0.001), endoleak (p=0.004) at short-term and a higher rate of endoleak (p=0.023) at mid-term follow-up.</p><p><strong>Conclusion: </strong>In conclusion, this study demonstrated that f-EVAR and ch-EVAR techniques had acceptable perioperative and follow-up results and should be considered viable alternatives when encountering complex aortic diseases.</p><p><strong>Clinical impact: </strong>This study sought to investigate the baseline and pathological characteristics, as well as perioperative and follow-up results of f-EVAR and ch-EVAR at a single Chinese institution. F-EVAR (mostly physician-modified f-EVAR) was applied in patients with a wide range of etiologies and disease types, while ch-EVAR was preferred for AAA in older patients
目的:本研究旨在调查复杂主动脉疾病血管内修复的栅栏技术和平行技术的人口统计学和解剖学特征以及围手术期和随访结果:一项回顾性研究对2013年至2021年期间在一家研究所接受血管内治疗的67例连续性复杂主动脉疾病患者进行了研究,这些疾病包括腹主动脉瘤(AAA)、胸腹动脉瘤(TAAA)、主动脉夹层,或之前接受过血管内修复术的患者。介入治疗的选择取决于疾病的紧急程度、患者的一般状况、解剖学特征以及设备指南的建议。对患者的临床人口统计学特征、主动脉疾病特征、围手术期细节和疾病进程进行了讨论。获得并分析了短期和中期随访结果。终点是动脉瘤相关和非相关死亡率、分支不稳定性和肾功能恶化:结果:分别有34名和27名患者接受了f-EVAR和ch-EVAR手术,6名患者接受了这两种手术的组合。瓣膜内主动脉修补术主要用于影响内脏分支的 AAA 和 TAAA,而 ch-EVAR 通常用于肾下 AAA。关于每名患者平均重建动脉的数量,f-EVAR、ch-EVAR 和联合组之间存在显著差异(平均值 = 2.3 ± 0.9、1.4 ± 0.6、3.5 ± 0.5,p):总之,本研究表明,f-EVAR 和 ch-EVAR 技术的围手术期和随访结果均可接受,在遇到复杂的主动脉疾病时,应将其视为可行的替代方案:临床影响:本研究旨在调查一家中国医疗机构中f-EVAR和ch-EVAR的基线和病理特征,以及围手术期和随访结果。F-EVAR(主要是医生改良的f-EVAR)适用于各种病因和疾病类型的患者,而ch-EVAR则首选用于年龄较大、ASA分级平均较高的AAA患者。我们的经验表明,这两种技术的安全性和有效性都是可以接受的,两组患者在中短期不良反应方面没有明显差异。
{"title":"Monocentric Evaluation of Physician-Modified Fenestrations or Parallel Endografts for Complex Aortic Diseases.","authors":"Siting Li, Wei Wang, Xiaoning Sun, Zhili Liu, Rong Zeng, Jiang Shao, Bao Liu, Yuexin Chen, Wei Ye, Yuehong Zheng","doi":"10.1177/15266028221149918","DOIUrl":"10.1177/15266028221149918","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;This study aimed to investigate the demographic and anatomic characteristics, as well as perioperative and follow-up results of fenestration and parallel techniques for the endovascular repair of complex aortic diseases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;A retrospective study was conducted on 67 consecutive patients underwent endovascular treatment for complex aortic diseases including abdominal aortic aneurysm (AAA), thoracoabdominal aneurysm (TAAA), aortic dissection, or prior endovascular repair with either fenestrated and parallel endovascular aortic repair (f-EVAR or ch-EVAR) at a single institute from 2013 to 2021. Choices of intervention were made by the disease' emergency, patients' general condition, the anatomic characteristics, as well as following the recommendation from the devices' guidelines. Patients' clinical demographics, aortic disease characteristics, perioperative details, and disease courses were discussed. Short- and mid-term follow-up results were obtained and analyzed. Endpoints were aneurysm-related and unrelated mortality, branch instability, and renal function deterioration.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Totally, 34 and 27 patients received f-EVAR and ch-EVAR, while 6 patients received a combination of both. Fenestrated endovascular aortic repair was conducted mainly in AAA affecting visceral branches and TAAA, whereas ch-EVAR was normally utilized for infrarenal AAA. Regarding the average number of reconstructed arteries per patient, there was a significant difference among f-EVAR, ch-EVAR, and the combination group (mean = 2.3 ± 0.9, 1.4 ± 0.6, 3.5 ± 0.5, p&lt;0.001). Primary technical success was achieved in 28 (82.4%), 22 (81.5%), and 3 (50.0%) patients for each group. Besides operational time (5.77 ± 2.58, 4.47 ± 1.44, p=0.033), no significant difference was observed for blood transfusion, intensive care unit (ICU) or hospital stay, blood creatinine level, 30-day complications, or follow-up complications between patients undergoing f-EVAR or ch-EVAR. Patients receiving combination of both techniques had a higher rate of blood transfusion (p=0.044), longer operational time (p=0.008) or hospital stay (p=0.017), as well as more stent occlusion (p=0.001), endoleak (p=0.004) at short-term and a higher rate of endoleak (p=0.023) at mid-term follow-up.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In conclusion, this study demonstrated that f-EVAR and ch-EVAR techniques had acceptable perioperative and follow-up results and should be considered viable alternatives when encountering complex aortic diseases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Clinical impact: &lt;/strong&gt;This study sought to investigate the baseline and pathological characteristics, as well as perioperative and follow-up results of f-EVAR and ch-EVAR at a single Chinese institution. F-EVAR (mostly physician-modified f-EVAR) was applied in patients with a wide range of etiologies and disease types, while ch-EVAR was preferred for AAA in older patients ","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9086078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ethanol Embolization of Chest Wall Arteriovenous Malformations: Four-Year Findings. 胸壁动静脉畸形的乙醇栓塞术:四年研究结果
IF 1.7 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-01 Epub Date: 2023-01-21 DOI: 10.1177/15266028221149908
Xin-Yu Li, De-Ming Wang, Ming-Zhe Wen, Lian-Zhou Zheng, Zhen-Feng Wang, Ren-Cai, Yi-Sun, Yu-Chen Shen, Li-Xin Su, Xin-Dong Fan, Xi-Tao Yang
<p><strong>Objectives: </strong>To summarize the clinical characteristics and investigate the efficacy of ethanol embolotherapy in the treatment of chest well arteriovenous malformation (AVM). Treatment-associated complications were also explored.</p><p><strong>Materials and methods: </strong>Between March 2017 and August 2021, 32 consecutive patients (mean age, 23.7 years; age range, 5-54 years) who underwent ethanol embolotherapy for chest well AVMs under general anesthesia were included in this study. Embolization was performed through a direct puncture, transarterial catheterization, or a combination of the 2 procedures. The mean follow-up duration after the last treatment was 18.0 months (range, 3-42 months). The degree of devascularization on follow-up (assessed using angiography or computed tomography), and the clinical signs and symptoms of AVMs were evaluated as the therapeutic outcomes. The major and minor complications associated with the procedures were recorded.</p><p><strong>Results: </strong>A total of 103 embolization procedures (mean, 3.2; range, 2-7) comprising 101 ethanol embolization and 2 coil embolizations were performed on 32 patients with chest wall AVMs. The AVM nidus was accessed through the transarterial approach alone in 4 patients, by direct puncture in 11, and a combined procedure in 17 patients. Overall, more than 80% of the procedures were performed using the combined approach. Complete AVM devascularization was achieved in 12 (37.5%) patients. Moreover, 76% to 99% AVM was achieved in 18 patients (56.3%), and 50% to 75% in 2 patients (6.3%). Bleeding, pain, heart failure, and cosmetic deformities were the indications for treatment. For 3 patients (3/32, 9.4%) who had bleeding, the treatment stopped the hemorrhage. Complete pain relief was reported in 8 patients (8/32, 25.0%), whereas complete relief from congestive heart failure post-embolization was observed in 5 of the 6 patients with congestive heart failure (5/6, 83.3%). Complete correction of cosmesis deformities after embolization was achieved in 10 patients (10/32, 31.3%). Two patients who underwent surgery to correct persistent deformity after embolization only showed insignificant improvement. In addition, 6 (18.8%) patients developed 13 complications including blister, necrosis, hemothorax, transient hemoglobinuria, and transient pulmonary artery hypertension.</p><p><strong>Conclusions: </strong>Ethanol embolotherapy is a safe and effective procedure for chest well AVMs. Surgery is required for some patients with residual cosmesis deformity.</p><p><strong>Clinical impact: </strong>Currently, there is no standard treatment for chest well AVMs due to their rarity and high heterogeneity. The present study shows that thanol embolotherapy is a safe and clinically effective treatment procedure for the chest well AVMs. Transarterial embolization in combination with direct puncture embolization can reach the AVM nidus. Ethanol embolotherapy can achieve complete o
目的总结乙醇栓塞治疗胸腔动静脉畸形(AVM)的临床特点并探讨其疗效。同时探讨与治疗相关的并发症:2017年3月至2021年8月期间,本研究纳入了连续32例在全身麻醉下接受乙醇栓塞治疗胸井动静脉畸形的患者(平均年龄23.7岁;年龄范围5-54岁)。栓塞是通过直接穿刺、经动脉导管或两种方法的组合进行的。最后一次治疗后的平均随访时间为 18.0 个月(3-42 个月)。随访时的血管缺损程度(使用血管造影术或计算机断层扫描评估)以及 AVM 的临床症状和体征作为治疗结果进行评估。此外,还记录了与手术相关的主要和次要并发症:共为 32 名胸壁动静脉畸形患者实施了 103 次栓塞手术(平均 3.2 次;范围 2-7 次),包括 101 次乙醇栓塞和 2 次线圈栓塞。4 名患者仅通过经动脉途径进入 AVM瘤巢,11 名患者通过直接穿刺进入,17 名患者通过联合手术进入。总体而言,超过 80% 的手术都是采用联合方法进行的。有 12 例(37.5%)患者实现了 AVM 完全去血管化。此外,18 名患者(56.3%)实现了 76% 至 99% 的 AVM 消失,2 名患者(6.3%)实现了 50% 至 75%的 AVM 消失。出血、疼痛、心力衰竭和外观畸形是治疗的适应症。有 3 名患者(3/32,9.4%)出现出血,治疗止住了出血。据报告,8 名患者(8/32,25.0%)的疼痛完全缓解,而在 6 名充血性心力衰竭患者中,5 名患者(5/6,83.3%)的栓塞后充血性心力衰竭症状完全缓解。10名患者(10/32,31.3%)在栓塞术后实现了外观畸形的完全矫正。有两名患者在栓塞术后接受了手术以矫正持续性畸形,但改善效果不明显。此外,6 名患者(18.8%)出现了 13 种并发症,包括水泡、坏死、血胸、一过性血红蛋白尿和一过性肺动脉高压:结论:乙醇栓塞疗法是治疗胸腔良性动静脉畸形安全有效的方法。临床影响:临床影响:由于胸腔井状 AVMs 的罕见性和高度异质性,目前尚无治疗胸腔井状 AVMs 的标准方法。本研究表明,比妥酚栓塞疗法是一种安全且临床有效的胸腔井室动静脉畸形治疗方法。经动脉栓塞联合直接穿刺栓塞可直达 AVM瘤巢。乙醇栓塞疗法可使大多数患者的动静脉畸形瘤巢完全消失。栓塞后可能仍需手术矫正外观畸形。本研究为临床决策提供了宝贵的证据。
{"title":"Ethanol Embolization of Chest Wall Arteriovenous Malformations: Four-Year Findings.","authors":"Xin-Yu Li, De-Ming Wang, Ming-Zhe Wen, Lian-Zhou Zheng, Zhen-Feng Wang, Ren-Cai, Yi-Sun, Yu-Chen Shen, Li-Xin Su, Xin-Dong Fan, Xi-Tao Yang","doi":"10.1177/15266028221149908","DOIUrl":"10.1177/15266028221149908","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;To summarize the clinical characteristics and investigate the efficacy of ethanol embolotherapy in the treatment of chest well arteriovenous malformation (AVM). Treatment-associated complications were also explored.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;Between March 2017 and August 2021, 32 consecutive patients (mean age, 23.7 years; age range, 5-54 years) who underwent ethanol embolotherapy for chest well AVMs under general anesthesia were included in this study. Embolization was performed through a direct puncture, transarterial catheterization, or a combination of the 2 procedures. The mean follow-up duration after the last treatment was 18.0 months (range, 3-42 months). The degree of devascularization on follow-up (assessed using angiography or computed tomography), and the clinical signs and symptoms of AVMs were evaluated as the therapeutic outcomes. The major and minor complications associated with the procedures were recorded.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 103 embolization procedures (mean, 3.2; range, 2-7) comprising 101 ethanol embolization and 2 coil embolizations were performed on 32 patients with chest wall AVMs. The AVM nidus was accessed through the transarterial approach alone in 4 patients, by direct puncture in 11, and a combined procedure in 17 patients. Overall, more than 80% of the procedures were performed using the combined approach. Complete AVM devascularization was achieved in 12 (37.5%) patients. Moreover, 76% to 99% AVM was achieved in 18 patients (56.3%), and 50% to 75% in 2 patients (6.3%). Bleeding, pain, heart failure, and cosmetic deformities were the indications for treatment. For 3 patients (3/32, 9.4%) who had bleeding, the treatment stopped the hemorrhage. Complete pain relief was reported in 8 patients (8/32, 25.0%), whereas complete relief from congestive heart failure post-embolization was observed in 5 of the 6 patients with congestive heart failure (5/6, 83.3%). Complete correction of cosmesis deformities after embolization was achieved in 10 patients (10/32, 31.3%). Two patients who underwent surgery to correct persistent deformity after embolization only showed insignificant improvement. In addition, 6 (18.8%) patients developed 13 complications including blister, necrosis, hemothorax, transient hemoglobinuria, and transient pulmonary artery hypertension.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Ethanol embolotherapy is a safe and effective procedure for chest well AVMs. Surgery is required for some patients with residual cosmesis deformity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Clinical impact: &lt;/strong&gt;Currently, there is no standard treatment for chest well AVMs due to their rarity and high heterogeneity. The present study shows that thanol embolotherapy is a safe and clinically effective treatment procedure for the chest well AVMs. Transarterial embolization in combination with direct puncture embolization can reach the AVM nidus. Ethanol embolotherapy can achieve complete o","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9103817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Preoperative Anemia on Hospitalization, Death, and Overall Survival in Patients With Peripheral Artery Disease Undergoing Endovascular Therapy: A Retrospective Cohort Study in the United States and Canada. 接受血管内治疗的外周动脉疾病患者术前贫血对住院、死亡和总生存期的影响:美国和加拿大的回顾性队列研究。
IF 1.7 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-10-01 Epub Date: 2023-01-20 DOI: 10.1177/15266028221149926
Abdul Kader Natour, Alexander D Shepard, Timothy J Nypaver, Ali Rteil, Paul Corcoran, Xiaoqin Tang, Loay Kabbani

Purpose: Preoperative anemia is associated with adverse outcomes after cardiac and noncardiac surgeries, but outcomes after an endovascular peripheral vascular intervention (PVI) are not well established. We aimed to assess the association of preoperative anemia with 30 day death, hospital length of stay (LOS), and overall (long term) survival in patients undergoing an endovascular PVI for peripheral artery disease.

Materials and methods: In this retrospective, cohort study in the United States and Canada, we queried the national Vascular Quality Initiative database for all endovascular PVIs performed between 2010 and 2019, and outcomes were correlated with patients' hemoglobin (Hb) levels. Anemia was classified as mild (Hb=10-13 g/dL for men and 10-12 g/dL for women), moderate (Hb=8-9.9 g/dL), and severe (Hb<8 g/dL).

Results: A total of 79 707 adult patients who met study criteria underwent endovascular PVI. The mean age was 68 years, and 59% of patients were male. Anemia was documented in 38 543 patients (48%) and was mild in 27 435 (71%), moderate in 9783 (25%), and severe in 1325 (4%). The median follow-up duration was 4 years (range, 1.25-5.78 years). On univariate analysis, 30 day mortality, total LOS, and overall survival were significantly associated with the level of preoperative anemia. These associations persisted in the multivariate models. Kaplan-Meier survival analysis demonstrated an association of death with degree of anemia (p<0.001).

Conclusion: The presence and degree of preoperative anemia were independently associated with increased 30 day mortality and LOS and decreased overall survival for patients with peripheral artery disease who had undergone endovascular PVI.

Clinical impact: The findings from this study have many implications for how to approach vascular surgery in patients with variable hemoglobin levels. Our findings will strengthen our ability to conduct accurate preoperative risk stratification for patients undergoing peripheral vascular interventions. This may also mitigate healthcare expenditures if findings are applied in a way that can lower patient length of postoperative stay while also maintaining quality of care and patient safety. Our results will also serve as guidance for clinical trials, and future prospective trials should evaluate the effect of preoperative optimization of hemoglobin as a potentially modifiable risk factor for outcomes.

目的:术前贫血与心脏和非心脏手术后的不良预后有关,但血管内外周血管介入术(PVI)后的预后尚未明确。我们旨在评估因外周动脉疾病接受血管内外周血管介入治疗的患者术前贫血与 30 天死亡、住院时间(LOS)和总体(长期)生存的关系:在这项在美国和加拿大进行的回顾性队列研究中,我们查询了国家血管质量倡议数据库中 2010 年至 2019 年期间进行的所有血管内 PVI,并将结果与患者的血红蛋白(Hb)水平相关联。贫血分为轻度(男性血红蛋白=10-13 g/dL,女性血红蛋白=10-12 g/dL)、中度(血红蛋白=8-9.9 g/dL)和重度(血红蛋白结果:共有 79707 名符合研究标准的成年患者接受了血管内 PVI 术。平均年龄为 68 岁,59% 的患者为男性。有记录的贫血患者有 38543 人(48%),其中轻度贫血 27435 人(71%),中度贫血 9783 人(25%),重度贫血 1325 人(4%)。中位随访时间为 4 年(1.25-5.78 年)。单变量分析显示,30 天死亡率、总住院日和总生存率与术前贫血程度显著相关。这些关联在多变量模型中依然存在。Kaplan-Meier 生存分析表明,死亡与贫血程度有关(p 结论:对于接受血管内 PVI 术的外周动脉疾病患者来说,术前贫血的存在和程度与 30 天死亡率和 LOS 的增加以及总生存率的降低密切相关:这项研究的结果对如何对血红蛋白水平不一的患者进行血管手术有很多影响。我们的研究结果将加强我们对接受外周血管介入治疗的患者进行准确术前风险分层的能力。如果研究结果的应用能缩短患者的术后住院时间,同时还能保证医疗质量和患者安全,那么这还能减少医疗支出。我们的研究结果还将为临床试验提供指导,未来的前瞻性试验应评估术前优化血红蛋白的效果,因为血红蛋白是影响预后的潜在可调风险因素。
{"title":"Impact of Preoperative Anemia on Hospitalization, Death, and Overall Survival in Patients With Peripheral Artery Disease Undergoing Endovascular Therapy: A Retrospective Cohort Study in the United States and Canada.","authors":"Abdul Kader Natour, Alexander D Shepard, Timothy J Nypaver, Ali Rteil, Paul Corcoran, Xiaoqin Tang, Loay Kabbani","doi":"10.1177/15266028221149926","DOIUrl":"10.1177/15266028221149926","url":null,"abstract":"<p><strong>Purpose: </strong>Preoperative anemia is associated with adverse outcomes after cardiac and noncardiac surgeries, but outcomes after an endovascular peripheral vascular intervention (PVI) are not well established. We aimed to assess the association of preoperative anemia with 30 day death, hospital length of stay (LOS), and overall (long term) survival in patients undergoing an endovascular PVI for peripheral artery disease.</p><p><strong>Materials and methods: </strong>In this retrospective, cohort study in the United States and Canada, we queried the national Vascular Quality Initiative database for all endovascular PVIs performed between 2010 and 2019, and outcomes were correlated with patients' hemoglobin (Hb) levels. Anemia was classified as mild (Hb=10-13 g/dL for men and 10-12 g/dL for women), moderate (Hb=8-9.9 g/dL), and severe (Hb<8 g/dL).</p><p><strong>Results: </strong>A total of 79 707 adult patients who met study criteria underwent endovascular PVI. The mean age was 68 years, and 59% of patients were male. Anemia was documented in 38 543 patients (48%) and was mild in 27 435 (71%), moderate in 9783 (25%), and severe in 1325 (4%). The median follow-up duration was 4 years (range, 1.25-5.78 years). On univariate analysis, 30 day mortality, total LOS, and overall survival were significantly associated with the level of preoperative anemia. These associations persisted in the multivariate models. Kaplan-Meier survival analysis demonstrated an association of death with degree of anemia (p<0.001).</p><p><strong>Conclusion: </strong>The presence and degree of preoperative anemia were independently associated with increased 30 day mortality and LOS and decreased overall survival for patients with peripheral artery disease who had undergone endovascular PVI.</p><p><strong>Clinical impact: </strong>The findings from this study have many implications for how to approach vascular surgery in patients with variable hemoglobin levels. Our findings will strengthen our ability to conduct accurate preoperative risk stratification for patients undergoing peripheral vascular interventions. This may also mitigate healthcare expenditures if findings are applied in a way that can lower patient length of postoperative stay while also maintaining quality of care and patient safety. Our results will also serve as guidance for clinical trials, and future prospective trials should evaluate the effect of preoperative optimization of hemoglobin as a potentially modifiable risk factor for outcomes.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10554986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Endovascular Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1